FDA Clears First Targeted Dermatomyositis Treatment From Roivant
FDA approves Roivant's LISRAYA for adult dermatomyositis, offering a once-daily targeted therapy that reduces steroid dependency.
Stocks · News reference
Roivant's Priovant Announces First Patients Enrolled In Global Phase 3 BEACON+ Study Of Brepocitinib In Cutaneous Sarcoidosis; Topline Data Expected In 2028
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Roivant Sciences Ltd. (ROIV)
Filed: 2026-08-28 AccNo: 0001140361-26-034854 Size: 2 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $41 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $41 price target.
Roivant's Priovant Says FDA Approved LISRAYA For Dermatomyositis In Adults, First Targeted Therapy For The Disease; Available In U.S. Immediately